Prognostic values of baseline, interim and end-of therapy ¹⁸F-FDG PET/CT in patients with follicular lymphoma

References

• Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618–3626. doi:10.1200/JCO.2016.66.944027551111
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lympho care study. J Clin Oncol. 2015;33:2516–2522. doi:10.1200/JCO.2014.59.753426124482
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the FondazioneItalianaLinfomi (FIL) . Ann Oncol. 2014;25:442–447. doi:10.1093/annonc/mdt56224412823
   PubMed Web of Science ®Google Scholar
• Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587–99600. doi:10.18632/oncotarget.2044729245926
   PubMedGoogle Scholar
• Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950–956. doi:10.1182/blood-2014-12-61647426089397
   PubMed Web of Science ®Google Scholar
• Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLI UM): secondary analysis of a randomised, phase 3 trial . Lancet Oncol. 2018;19:1530–1542. doi:10.1016/S1470-2045(18)30618-130309758
   PubMed Web of Science ®Google Scholar
• Kim HJ, Lee R, Choi H, et al. Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma. Nucl Med Mol Imaging. 2018;52:342–349. doi:10.1007/s13139-018-0543-830344782
   PubMed Web of Science ®Google Scholar
• Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma . Eur J Nucl Med Mol Imaging. 2019;46:87–96. doi:10.1007/s00259-018-4173-230276438
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen Y, Huang H, et al. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7:83544–83553. doi:10.18632/oncotarget.1318027835875
   PubMedGoogle Scholar
• Moskowitz AJ, Schöder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196–2203.28874350
   PubMed Web of Science ®Google Scholar
• Annunziata S, Cuccaro A, Tisi MC, et al. FDG-PET/CT at the end of immuno- chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV (rPET). Ann Nucl Med. 2018;32:372–377. doi:10.1007/s12149-018-1243-229464479
   PubMed Web of Science ®Google Scholar
• Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280:220–229. doi:10.1148/radiol.201515068926854705
   PubMed Web of Science ®Google Scholar
• Adams HJ, Nievelstein RA. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95:11–18. doi:10.1007/s00277-015-2553-226576560
   PubMed Web of Science ®Google Scholar
• Adams HJ. No convincing evidence to support postinduction FDG-PET in follicular lymphoma. Ann Hematol. 2016;95:2085–2086. doi:10.1007/s00277-016-2808-627604230
   PubMed Web of Science ®Google Scholar
• Adams HJA, Kwee TC. Debate on the value of end-of-treatment FDG-PET response evaluation in follicular lymphoma. ActaOncologica. 2017;56(12):1–3. doi:10.1080/0284186X.2017.1349927
   Google Scholar
• Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. doi:10.1007/s00259-009-1297-419915839
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Ito K, Bantilan K, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma . Blood Adv. 2019;3:187–197. doi:10.1182/bloodadvances.201802407530670535
   PubMed Web of Science ®Google Scholar
• Adams HJA. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. SeminOncol. 2017;44:404–419. doi:10.1053/j.seminoncol.2018.01.005
   Google Scholar
• Kostakoglu L, Goy A, Martinelli G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58:372–381. doi:10.1080/10428194.2016.119681527339738
   PubMed Web of Science ®Google Scholar
• Metser U, Hussey D. Impact of (18) F-FDG PET/CT on the staging and management of follicular lymphoma. Br J Radiol. 2014;87:20140360. doi:10.1259/bjr.2014036025061910
   PubMed Web of Science ®Google Scholar
• Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by F-FDG PET-CT: a collaborative study by ILROG . Blood. 2019;133:237–245. doi:10.1182/blood-2018-04-84354030446493
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. doi:10.1200/JCO.2013.54.880025113753
   PubMed Web of Science ®Google Scholar
• Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;3(9):1–5. doi:10.1016/j.amjoto.2017.10.009
   Google Scholar
• Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL . Eur J Nucl Med Mol Imaging. 2016;43:1209–1219. doi:10.1007/s00259-016-3315-726902371
   PubMed Web of Science ®Google Scholar
• Liang JH, Zhang YP, Xia J, et al. Prognostic value of baseline and interim total metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with follicular lymphoma. Cancer Res Treat. 2019;12. doi:10.4143/crt.2018.649
   Google Scholar
• Cottereau AS, Versari A, Luminari S, et al. Prognostic model for high-tumor- burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/F IL study. Blood. 2018;131:2449–2453. doi:10.1182/blood-2017-11-81629829559480
   PubMed Web of Science ®Google Scholar
• Adams HJ. Overestimated value of baseline total metabolic tumor volume at (18) F-labeled fluorodeoxyglucose positron emission tomography in follicular lymphoma. J Clin Oncol. 2017;35:918–919. doi:10.1200/JCO.2016.70.489028029311
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703. doi:10.1007/s00277-011-1357-222071570
   PubMed Web of Science ®Google Scholar
• Barrington SF. Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden. J Nucl Med. 2019;jnumed.119. 227249. doi:10.2967/jnumed.119.227249
   PubMed Web of Science ®Google Scholar
• Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18) F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Grouped’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–4322. doi:10.1200/JCO.2012.43.093423109699
   PubMed Web of Science ®Google Scholar
• Lu Z, Lin M, Downe P, et al. The prognostic value of mid- and post-treatment [(18) F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28:805–811. doi:10.1007/s12149-014-0874-125008291
   PubMed Web of Science ®Google Scholar
• Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48:1548–1555. doi:10.1080/1042819070142205917701586
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fan Y, Ying Z, et al. Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leuk Lymphoma. 2018;59(3):660–669. doi:10.1080/10428194.2017.135717128771052
   PubMed Web of Science ®Google Scholar
• Lombion N, Robin P, Tempescul A, et al. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria. Q J Nucl Med Mol Imaging. Epub 2016 Nov 30.
   Web of Science ®Google Scholar
• Jiang C, Su M, Kosik RO, et al. The Deauville 5-point scale improves the prognostic value of interim FDG PET/CT in extranodal natural killer/T-cell lymphoma. Clin Nucl Med. 2015;40:767–773. doi:10.1097/RLU.000000000000089226164182
   PubMed Web of Science ®Google Scholar
• Metser U, Mohan R, Beckley V, et al. FDG PET/CT response assessment criteria for patients with Hodgkin’s and Non-Hodgkin’s lymphoma at end of therapy: a multiparametric approach. Nucl Med Mol Imaging. 2016;50:46–53. doi:10.1007/s13139-015-0368-726941859
   PubMedGoogle Scholar
• Del PuigCózar-Santiago M, García-Garzón JR, Moragas-Freixa M, et al. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentrestudy. Rev Esp Med Nucl Imagen Mol. 2017;36:304–311. doi:10.1016/j.remn.2017.03.00328483373
   PubMed Web of Science ®Google Scholar
• Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569–573. doi:10.2967/jnumed.113.13060924566003
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhang Y, Yang Z, et al. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV-based interpretation for predicting the outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58:1–9. doi:10.1080/10428194.2016.1277384
   PubMed Web of Science ®Google Scholar
• Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–533. doi:10.2967/jnumed.108.05770319289424
   PubMed Web of Science ®Google Scholar
• Wei WX, Huang JJ, Li WY, et al. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma.Chin. J Cancer. 2015;34:608–613. doi:10.1186/s40880-015-0057-z
   Web of Science ®Google Scholar